Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 6/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157046 | 0.93 | SCN9A (0.38) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL121354 | 0.93 | SCN9A (0.38) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL1278450 | 0.93 | SCN9A (0.38) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL29485704 | 0.93 | SCN9A (0.38) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL3302720 | 0.88 | SCN9A (0.39) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL3302723 | 0.88 | SCN9A (0.39) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL12710196 | 0.85 | SCN9A (0.37) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL22176889 | 0.84 | RAF1 (0.37) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL20521116 | 0.84 | RAF1 (0.37) | SCN9AARHTR2ASLC6A4KCNH2 | |
| SCHEMBL20521115 | 0.84 | RAF1 (0.37) | SCN9AARHTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237395-B1 | CYCLIC COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10023563-B2 | Cyclic compounds substituted by a condensed ring system | BASF SE (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20170369479-A1 | CYCLIC COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023563-B2 | Cyclic compounds substituted by a condensed ring system | CYCS, DDT, CAT | SCN9A 2305/4885AR 3151/4885HTR2A 4668/4885 |
| US-20170369479-A1 | CYCLIC COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | CYCS, DDT, CAT | SCN9A 2305/4885AR 3151/4885HTR2A 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.